Trials / Completed
CompletedNCT01468584
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Subjects With Genotype 2 Hepatitis C, Who Did Not Respond to Previous Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who did not respond to previous treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP-424 (generic name:Telaprevir) | 750mg q8h for 12 weeks |
| DRUG | Ribavirin | 400 - 1000 mg/day based on body weight for 24 weeks |
| DRUG | Peginterferon alfa-2b | 1.5mcg/kg/week for 24 weeks |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2011-11-09
- Last updated
- 2026-01-06
- Results posted
- 2014-11-03
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01468584. Inclusion in this directory is not an endorsement.